Placeholder

Building a Culture of Innovation

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

Industry analysts say many pharmaceutical and biopharma companies are turning their focus away from R&D and innovation, yet a recent survey by Quintiles and the Economist Intelligence Unit reveals that innovation is key to bringing new, more effective products to market to treat diseases.
The research also reports that while no single model works for all companies, the top innovators, those companies that are open to insights from many different sources, generated almost twice as many products and NMEs as their peers in the last three years.
The survey identified several barriers that prevent pharmaceutical companies from achieving or even pursuing innovation on a clinical front, including culture, which was identified as the primary obstacle. Culture was followed by high costs, complex regulations, and long development…

Sidebar:
Fostering Innovation
Sound bites From the Field
John Arrowsmith, Ph.D.
, is Science Director, Thomson Reuters, a source of intelligent information for businesses and professionals. For more information, visit thomsonreuters.com.
Bill Cooney is President and CEO of MedPoint Communications Digital Inc., which ­provides specialized digital services to the global biopharma ­industry. For more information, visit medpt.com.
Frances L. DeGrazio is VP, ­Marketing and Strategic Business ­Development, West Pharmaceutical Services, a provider of solutions for ­injectable drug administration. For more ­information, visit westpharma.com.
Denise (DeeDee) DeMan is Founder, Chairman, and CEO of Bench International, a global, executive ­recruiting and consulting firm serving the life-sciences industry. For more information, visit benchinternational.com.
Glen deVries is President of ­Medidata Solutions Worldwide, a global provider of SaaS-based clinical development solutions that enhance the efficiency of customers’ clinical trials. For more information, visit mdsol.com.
David Fishman is President of Snowfish LLC, a marketing firm focused on the pharmaceutical, biotechnology, and medical device industries. For more information, visit snowfish.net.
Sean McCarthy, D.Phil., is CEO of CytomX Therapeutics Inc., a privately held biotechnology company ­developing Probodies, or ­proteolytically activated antibodies. For more ­information, visit cytomx.com.
Stuart W. Peltz, Ph.D., is ­President and CEO, PTC Therapeutics Inc., a ­biopharmaceutical company focused on the discovery, development, and ­commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. For more information, visit ptcbio.com.
John Rothman, Ph.D., is Executive VP, Science and Operations, at Advaxis Inc., a biotechnology company developing the next generation of ­immunotherapies for cancer and infectious ­diseases. For more information, visit advaxis.com.
KK Rumrill is Client Services Director at BBK Worldwide, a provider of patient recruitment ­services for clinical trials. For more information, visit bbkworldwide.com.
Lee Valenta is President of ­OptumInsight Life Sciences, which ­specializes in technology, ­information, analytics, business, and consulting ­services. For more information, visit optum.com.

Experts
Elliott Berger. VP, Global Marketing and Strategy for ­Catalent Pharma Solutions, which provides development services from advanced delivery technologies to ­supply solutions for drugs and biologics. For more information, visit catalent.com.
John Blakeley. Executive VP and Chief Commercial Officer, ERT, a clinical research service provider that assesses the safety of newly developed drugs. For more ­information, visit ert.com.
Dr. Terri Cooper. Principal, Deloitte Consulting LLP and National Leader, Life Sciences R&D Practice, Deloitte, which ­provides audit, financial advisory, tax, and consulting services. For more information, visit deloitte.com.
Oliver Fetzer, Ph.D. ­President and CEO, Cerulean Pharma Inc., a clinical-stage company ­specializing in the design and development of nanopharmaceuticals. For more information, visit ceruleanrx.com.
Jen Goldsmith. VP, Veeva Vault, a provider of cloud-based business solutions for the global life-sciences industry. For more ­information, visit veevasystems.com.
Neil MacAllister. Chief ­Business Officer, INC Research, and President, AVOS Consulting, INC ­Research is a
therapeutically ­focused clinical research organization ­conducting global clinical ­development ­programs. For more information, visit ­incresearch.com.
Subhro Mallik. Associate VP, Life Sciences Practice, Infosys Ltd., which provides business consulting, IT solutions, and services to ­companies globally. For more information, visit infosys.com.
Kiran Meekings, Ph.d. ­Consultant, Life-Sciences ­Consulting Team, Thomson Reuters, a provider of ­intelligent
information for ­businesses and professionals. For more ­information, visit thomsonreuters.com.
Robert Nauman. Principal, BioPharma Advisors, a network of consultants with years of ­experience in the pharmaceutical and biotechnology ­industries. For more ­information, visit ­biopharmaadvisors.net.
Kimberly Ramko. Americas Life ­Sciences Sector Leader for Advisor Services, Ernst & Young, a global provider of assurance, tax, ­transaction, and advisory services. For more information, visit ey.com.
Nagaraja Srivatsan. Senior VP and Head of Life-Sciences, North America, for Cognizant, a provider of information technology, consulting, and business process outsourcing services. For more information, visit cognizant.com.
David Wolf. CEO, Hamilton Thorne, a provider of advanced laser systems for the ­regenerative medicine, fertility, and stem cell research markets. For more information, visit hamiltonthorne.com.

FEEDBACK